Venetoclax

Venetoclax

Molecular Name: Venetoclax 
Active Ingredient: Venetoclax 
Strength: 10 mg, 50 mg and 100 mg tablets.
Manufactured: 

The antiapoptotic protein BCL-2 is selectively and orally bioavailability inhibited by the small molecule Venetoclax. It has been shown that overexpression of BCL-2 in CLL cells mediates tumor cell survival and has been linked to chemotherapeutic resistance. By directly binding to the BCL-2 protein and displacing pro-apoptotic proteins like BIM, causing mitochondrial outer membrane permeabilization and activating caspases, venetoclax aids in the restoration of the apoptotic process. Venetoclax has demonstrated cytotoxic activity in tumor cells overexpressing BCL-2 in nonclinical studies.

Venetoclax can be used to treat adult patients with small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL).


Adult CLL patients who have undergone at least one prior therapy should be treated with Venetoclax  monotherapy if:

  1. In adult patients who are ineligible for or have tried unsuccessfully to use a B-cell receptor pathway inhibitor and have a 17p deletion or TP53 mutation; or
  2. In adult patients who have failed chemotherapy, immunotherapy, and a B-cell receptor pathway inhibitor but do not have a 17p deletion or TP53 mutation.

Adult patients newly diagnosed with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy may be treated with Venetoclax  in combination with a hypomethylating agent or low-dose cytarabine. We assist with venetoclax pricing, details, and uses, ARKON SOLUTIONS, through Name patient Import Services or Govt Hospital Supply.

Pharmaceutical Particulars

List of excipients

Tablet Core 
  • Copovidone (K 28)
  • Colloidal anhydrous silica (E551)
  • Polysorbate 80 (E433)
  • Sodium stearyl fumarate
Film-Coating 
  • Iron oxide yellow (E172)
  • Polyvinyl alcohol (E1203)
  • Titanium dioxide (E171)
  • Macrogol 3350 (E1521)
  • Talc (E553b)
Incompatibilities
Not applicable.
Pharmaceutical Particulars

Special storage precautions

  • Keep out of children's reach.
  • Do not store expired or unnecessary medications.
  • How should any unneeded medications be disposed of? Ask your healthcare provider.
  • The medication should be kept at room temperature in a closed container away from heat, moisture, and bright light.
  • Avoid freezing.
  • Throughout the initial four weeks of treatment, keep the tablets in their original packaging. Never move the medication to another container or a pillbox.

FAQ’s

Certain types of small lymphocytic lymphoma and chronic lymphocytic leukemia, CLL, a form of cancer that starts in the white blood cells, are treated with venetoclax alone. And also, in combination with obinutuzumab or rituximab, SLL is a type of cancer that begins mainly in the lymph nodes. It is also utilised as a first treatment for acute myeloid leukemia, which is AML, a type of cancer that starts in the white blood cells in adults 75 years of age or older. Combining azacitidine, decitabine, or cytarabine with any other chemotherapy medication is also possible in patients whose medical circumstances prevent them from receiving those medications. Venetoclax belongs to a group of drugs known as B-cell lymphoma-2 inhibitors. It prevents the body from using a specific protein that helps in the survival of cancer cells. As an outcome, the cancer cells are killed effectively.

A drug used alone or in combination with other medications to treat certain persons with newly diagnosed acute myeloid leukemia, chronic lymphocytic leukemia, or small lymphocytic lymphoma. It is also being researched for the treatment of different cancers. A protein called BCL2 that is present in some types of cancer cells is what venetoclax binds to. By inhibiting this protein, cancer cells may be killed and made more responsive to anticancer medications. A particular kind of BCL2 inhibitor is venetoclax. Additionally, it is also known as Venclexta. It works by preventing the body from using a specific protein that helps survive cancer cells. This helps in the elimination of cancerous cells.

Chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) can be treated with Venclexta, also known as venetoclax. And clinical trials have shown that it is more effective than standard therapy in achieving complete remission in patients with both diseases. Additionally, Venclexta has a quick response time; for many patients, a slowing of disease progression is noticeable after around one month on average Patients allocated to V+A took an average of one month between 0.7 and 8.9 months to reach a clinical remission. In patients assigned to V+D, the time it took to reach a clinical response was, on average, 1.9 months, with a range of 0.8 to 4.2 months.

Venetoclax is taken as tablets once daily with food. The tablets are taken whole, along with a glass of water. You consume them simultaneously every day, generally with water and breakfast and without chewing, crushing, or breaking. You must follow the directions provided by your doctor or pharmacist when taking tablets. Speak with your pharmacist if you have any issues taking the tablets. Whether you have a full or empty stomach can affect how much of the medication enters your bloodstream. You should only consume the recommended dosage. Before you stop taking or miss a dosage of cancer medication, consult your healthcare provider.

Venclexta is often taken for 12 months in combination with Gazyva, which is obinutuzumab if you have small lymphocytic leukemia, SLL or chronic lymphocytic leukemia that has not previously been treated. Venclexta is often used for up to 24 months in combination with rituximab if you have already undergone therapy for CLL or SLL. As long as it is considered safe by your doctor, Venclexta is continued on a once-daily maintenance dose cycle for patients with AML, which is acute myeloid leukemia. This is typically done with another medication until the disease progresses and unacceptable toxicity is observed. You can discuss the recommended duration of Venclexta use with your doctor.

Patients allocated to V+A took an average of one month between 0.7 and 8.9 months to reach clinical remission. In patients assigned to V+D, the time it took to reach a clinical remission was, on average, 1.9 months, with a range of 0.8 to 4.2 months. Patients allocated to V + low-dose cytarabine experienced clinical remission in an average of one month with a range of 0.8 to 9.4 months. It would help if you also remembered that everyone responds to venclexta differently. Depending on the individual, the time it takes to start working and take action may differ. 

Adults with Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Acute Myeloid Leukemia (AML) can take the prescription drug venetoclax is also known as Venclexta. Venetoclax works by slowing or stopping the growth of cancer cells.

  1. Exactly as prescribed by your doctor, take this medication. Never take it in more significant amounts, more frequently, or for a longer period of time than recommended by your doctor. Without first consulting, your doctor do not alter your dosage or stop taking this medication.
  2. A medication guide is included with this medication. Please carefully read and adhere to these guidelines. In case you have any questions, consult your doctor.
  3. Take this medication at the same time every day with food and water. Completely inhale the tablet. Do not chew, break, or crush it.
  4. Drink plenty of water daily to lessen the likelihood of a negative effect called tumor lysis syndrome.
  5. Starfruit, Seville oranges, and grapefruit-related products should not be consumed while taking this medication.
  1. When you have a nasty infection.
  2. If a patient is breastfeeding or pregnant.
  3. If one has Hypersensitivity to any product ingredient.
  •  Back pain
  •  Decreased Appetite
  •  Difficulty having a bowel movement
  •  Mouth or Throat Pain
  •  Mood or Mental Changes
  •  Muscle Cramps, Pains, or Stiffness
  •  Muscle Spasms (tetany) or Twitching Seizures
  •  Nausea
  •  Nervousness
  •  Unusual Weight Gain or Loss
  •  Vomiting
  •  Yellow Eyes or Skin
Three years